Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will release first quarter 2026 financial results and operational highlights before U.S. market open on May 14, 2026.
Management will host a conference call and webcast on May 14, 2026 at 8:30am EDT / 1:30pm BST to discuss results and provide a general business update; preregistration is required for dial‑in access and PINs.
Positive
- None.
Negative
- None.
News Market Reaction – AUTL
In the May 5 session, AUTL gained 4.46%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.4% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Earnings date notice | Neutral | +0.0% | Announcement of Q4 and full-year 2025 results timing and conference call logistics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news produced a flat 0% next-day move, suggesting such logistics updates have not historically moved the stock.
Over recent months, Autolus has combined commercial ramp-up of AUCATZYL with cost controls and capital markets activity. On March 27, 2026, it reported Q4 and full-year 2025 results and guided 2026 AUCATZYL revenue to $120M–$135M. A March 8-K detailed restructuring to cut operating expenses by about $15M annually. The current notice of Q1 2026 results and conference call on May 14, 2026 follows the same pattern as the prior results-date announcement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its first quarter 2026 financial results and operational highlights before open of U.S. markets on Thursday, May 14, 2026.
Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
